Sanyou Bio and Shanghai ZJ Bio-Tech Form Strategic Partnership to Accelerate Biologics Development Through AI and Automation
Key Insights
Sanyou Biopharmaceuticals (search) and Shanghai ZJ Bio-Tech (search) have signed a strategic cooperation agreement to integrate AI-powered drug discovery with automated development systems for innovative biologics (search).
The partnership combines Sanyou's AI-STAL (search) super-trillion molecule library technology with Shanghai ZJ Bio-Tech (search)'s automated smart systems to significantly reduce R&D timelines and enhance development efficiency.
This collaboration aims to reshape the drug development paradigm by freeing scientific talent for creative work while improving R&D budget utilization through more precise automated processes.
Sanyou Biopharmaceuticals (search) (Shanghai) Co., Ltd. and Shanghai ZJ Bio-Tech (search) technology Co., Ltd. have officially signed a strategic cooperation agreement focused on the automated development of innovative biologics (search), marking a significant step toward addressing drug development bottlenecks through advanced automation and artificial intelligence technologies.
Strategic Integration of AI and Automation Technologies
The collaboration centers on combining Sanyou Bio's globally leading AI-powered Super-Trillion Molecule Library (AI-STAL (search)) technology with Shanghai ZJ Bio-Tech (search)'s automated smart systems. This integration aims to substantially reduce R&D timelines for innovative drugs while enhancing the predictability and output efficiency of the development process.
According to the agreement, Sanyou Bio will systematically upgrade its antibody drug molecule screening process through automation, enabling scientific talent to focus more on creative work. The automated processes are expected to provide greater precision and stability, significantly improving R&D budget utilization efficiency.
Leadership Perspectives on Industry Transformation
Dr. Lang Guojun, Founder and CEO of Sanyou Bio, emphasized the collaboration's potential to address core challenges in biologics R&D. "By deeply integrating Sanyou's AI-STAL (search)™ intelligent ultra-trillion molecular library with ZJ Bio-Tech's automation and intelligent technologies, we will jointly drive breakthroughs in key technologies for innovative biologics (search) R&D," he stated. "We are committed to building a more efficient and intelligent R&D system, thereby significantly shortening drug development timelines and accelerating the launch of innovative therapies."
Ms. Ni Weiqin, Deputy General Manager and Board Secretary of Shanghai ZJ Bio-Tech (search), outlined the partnership's vision for paradigm innovation. "We look forward to breaking down the barriers of traditional R&D models through this collaboration and jointly creating a new digital-intelligent paradigm for drug discovery that integrates 'automated hardware' and 'AI intelligent decision-making'," she said. The collaboration aims to achieve intelligent empowerment at source stages including target discovery and molecular design through artificial intelligence and big data analytics.
Company Capabilities and Track Records
Shanghai ZJ Bio-Tech (search) (Stock Code: 688317) operates as a national high-tech enterprise specializing in molecular diagnostic reagents (search) and instrument equipment. The company holds over 80 authorized patents and has received more than 10 major awards, including the second prize of the National Technology Invention Award. During global public health emergencies involving highly pathogenic avian influenza (search), Ebola virus (search), and Zika virus (search) outbreaks, the company made significant contributions, with multiple products included in the WHO Emergency Use Listing.
Sanyou Biopharmaceuticals (search) has established collaborations with more than 2,000 pharmaceutical and biotech companies worldwide, empowering over 1,200 new drug discovery and development projects. The company has completed more than 50 collaboration projects, with over 10 advancing to IND approval and clinical development stages. Headquartered in Shanghai, Sanyou operates global business centers across Asia, North America, and Europe, with over 20,000 square meters of R&D and GMP facilities currently operating or planned.
Technological Foundation and Innovation Platform
The partnership leverages Sanyou's AI-driven super-trillion antibody library (AI-STAL (search)) supported by an integrated and intelligent R&D platform that combines in silico and wet-lab capabilities. This technology platform has enabled the company to file over 130 invention patents, with more than 30 granted, while obtaining over 10 national and international qualifications and system certifications.
The strategic cooperation extends beyond simply shortening R&D cycles to encompass enhancing predictability and output efficiency of the R&D process, stimulating momentum for source innovation, and reshaping core corporate competitiveness through technological integration and strategic synergy. The collaborative outcomes are expected to advance the development of innovative antibody drugs (search) and diagnostic/therapeutic technologies within intelligent healthcare frameworks, ultimately benefiting patient populations globally.